WO2023138638A1 - Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation - Google Patents

Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation Download PDF

Info

Publication number
WO2023138638A1
WO2023138638A1 PCT/CN2023/073040 CN2023073040W WO2023138638A1 WO 2023138638 A1 WO2023138638 A1 WO 2023138638A1 CN 2023073040 W CN2023073040 W CN 2023073040W WO 2023138638 A1 WO2023138638 A1 WO 2023138638A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
seq
binding protein
binding domain
amino acid
Prior art date
Application number
PCT/CN2023/073040
Other languages
English (en)
Chinese (zh)
Inventor
钟阵威
宁亚楠
李霄培
张梦瑶
邓奇
陈晓锐
左栋梁
何晓文
Original Assignee
原启生物科技(上海)有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 原启生物科技(上海)有限责任公司 filed Critical 原启生物科技(上海)有限责任公司
Priority to CN202380018211.5A priority Critical patent/CN118591565A/zh
Publication of WO2023138638A1 publication Critical patent/WO2023138638A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins

Definitions

  • This application relates to the field of biomedicine, in particular to a bispecific antigen-binding protein targeting TIGIT and PD-L1 and its application.
  • Immune checkpoint T cell immunoglobulin and immunoreceptor tyrosine inhibitory motif domain (TIGIT, also known as Vstm3, WUCAM) is a type I transmembrane protein.
  • TIGIT also known as Vstm3, WUCAM
  • CD155 also known as poliovirus receptor or PVR
  • CD112 also known as poliovirus receptor-related ligand 2, PVRL2, cohesin-2
  • TIGIT competes with the activating receptor CD226 to bind to the ligand CD155, transmits inhibitory signals, inhibits excessive cell activation and inhibits the secretion of pro-inflammatory cytokines (Manieri, Trends Immunol, 2017, 38(1):20-8).
  • TIGIT is mainly expressed on regulatory T cells (Treg), activated T cells and natural killer cells (NK) (YU, Nat Immunol, 2009, 10(1):48-57), which can directly inhibit the proliferation, killing, degranulation and cytokine secretion of T cells and NK cells, and can also inhibit T cell activity by promoting DC cells to secrete IL-10 (Nicholas, Trends Immunol.2017, 38(1) :20-28).
  • TIGIT expressed on Treg can maintain the immunosuppressive function of Treg (Manieri, Trends Immunol, 2017, 38(1):20-8).
  • TIGIT is significantly up-regulated in a variety of tumor cells, infiltrating lymphocytes and peripheral blood mononuclear cells, and its ligands CD155 and CD112 are also widely expressed in a variety of tumor cells, suggesting that TIGIT may play a key role in the process of tumor immune escape (Tassi, Cancer Res.2017,77:851-861.Kong,Clin Cancer Res,2016,22:3057-66. Immunol Immunother, 2009,58(9):1517-26.).
  • the known anti-TIGIT antibodies still have defects such as low specificity and limited lethality. Therefore, there is an urgent need to develop new anti-TIGIT antigen-binding proteins with high affinity and strong specificity for TIGIT protein.
  • the present application provides an isolated antigen-binding protein, which has one or more of the following properties: (1) capable of specifically binding to TIGIT protein; (2) capable of binding to human TIGIT and cynomolgus monkey TIGIT protein; (3) capable of blocking the interaction between cell surface TIGIT protein and CD155; (4) having good thermal stability; and (5) capable of inhibiting tumor growth and/or proliferation.
  • the application provides an isolated antigen-binding protein, which includes: a first antigen-binding domain and a second antigen-binding domain, the first antigen-binding domain can specifically bind PD-L1, and the second antigen-binding domain can specifically bind TIGIT, the first antigen-binding domain comprises at least one CDR in the heavy chain variable region VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen binding domain of the antigen binding protein comprises HCDR3, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 17.
  • the first antigen binding domain of the antigen binding protein comprises HCDR2, and the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16.
  • the first antigen binding domain of the antigen binding protein comprises HCDR1, and the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 15.
  • the first antigen binding domain of the antigen binding protein comprises VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises the amino acid sequence shown in SEQ ID NO: 18.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:19.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:20.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR4, the N-terminus of the H-FR4 is connected to the C-terminus of the HCDR3, and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:10.
  • the first antigen binding domain of the antigen binding protein comprises VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen binding domain of the antigen binding protein comprises LCDR3, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:26.
  • the first antigen binding domain of the antigen binding protein comprises LCDR2, and the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:25.
  • the first antigen binding domain of the antigen binding protein comprises LCDR1, and the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:24.
  • said first antigen binding domain of said antigen binding protein comprises L-FR1, said L-FR1
  • the C-terminal of the L-FR1 is directly or indirectly connected to the N-terminal of the LCDR1, and the L-FR1 comprises the amino acid sequence shown in SEQ ID NO:27.
  • the first antigen-binding domain of the antigen-binding protein comprises L-FR2
  • the L-FR2 is located between the LCDR1 and the LCDR2
  • the L-FR2 comprises the amino acid sequence shown in SEQ ID NO:28.
  • the first antigen-binding domain of the antigen-binding protein comprises L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 comprises the amino acid sequence shown in SEQ ID NO:29.
  • the first antigen-binding domain of the antigen-binding protein comprises L-FR4, the N-terminus of the L-FR4 is connected to the C-terminus of the LCDR3, and the L-FR4 comprises the amino acid sequence shown in SEQ ID NO:30.
  • the first antigen binding domain of the antigen binding protein comprises a VL, and the VL comprises the amino acid sequence shown in SEQ ID NO:31.
  • said first antigen binding domain of said antigen binding protein comprises an antibody heavy chain constant region derived from IgG.
  • said first antigen binding domain of said antigen binding protein comprises an antibody heavy chain constant region derived from human IgG.
  • said first antigen binding domain of said antigen binding protein comprises an antibody heavy chain constant region derived from human IgGl.
  • the first antigen binding domain of the antigen binding protein comprises an antibody heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO:22.
  • the first antigen binding domain of the antigen binding protein comprises a heavy chain, and the heavy chain comprises the amino acid sequence shown in SEQ ID NO:23.
  • said first antigen binding domain of said antigen binding protein comprises an antibody light chain constant region derived from Ig ⁇ .
  • the first antigen binding domain of the antigen binding protein comprises an antibody light chain constant region, and the light chain constant region comprises the amino acid sequence shown in SEQ ID NO:32.
  • the first antigen binding domain of the antigen binding protein comprises a light chain, and the light chain comprises the amino acid sequence shown in SEQ ID NO:31.
  • said first antigen binding domain of said antigen binding protein comprises an antibody or antigen binding fragment thereof.
  • the antigen-binding fragment comprises Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv, VHH and/or dAb.
  • the antibody is selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
  • said first antigen binding domain of said antigen binding protein is a monoclonal antibody.
  • the second antigen binding domain of the antigen binding protein comprises at least one CDR in the variable region VH of an antibody heavy chain, and the VH comprises the amino acid sequence shown in SEQ ID NO:42.
  • the second antigen binding domain of the antigen binding protein comprises HCDR3, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:6.
  • the second antigen binding domain of the antigen binding protein comprises HCDR2, and the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:41.
  • the second antigen binding domain of the antigen binding protein comprises HCDR2, and the HCDR2 comprises the amino acid sequence shown in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
  • the second antigen binding domain of the antigen binding protein comprises HCDR1, and the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1.
  • the second antigen-binding domain of the antigen-binding protein comprises H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 comprises the amino acid sequence shown in SEQ ID NO:7.
  • the second antigen-binding domain of the antigen-binding protein comprises H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 comprises the amino acid sequence shown in SEQ ID NO:8.
  • the second antigen-binding domain of the antigen-binding protein comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 comprises the amino acid sequence shown in SEQ ID NO:9.
  • the second antigen-binding domain of the antigen-binding protein comprises H-FR4, the N-terminus of the H-FR4 is connected to the C-terminus of the HCDR3, and the H-FR4 comprises the amino acid sequence shown in SEQ ID NO:10.
  • the second antigen binding domain of the antigen binding protein comprises VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:42.
  • said second antigen binding domain of said antigen binding protein comprises VH, and said VH comprises Contains the amino acid sequence shown in any one of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
  • said second antigen binding domain of said antigen binding protein comprises an antibody or antigen binding fragment thereof.
  • the antigen-binding fragment comprises Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv, VHH and/or dAb.
  • the antibody is selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies and fully human antibodies.
  • said second antigen binding domain of said antigen binding protein is VHH.
  • the VHH comprises the amino acid sequence shown in SEQ ID NO:42.
  • the VHH comprises the amino acid sequence shown in any one of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
  • said first antigen binding domain and said second antigen binding domain of said antigen binding protein are directly linked.
  • said first antigen binding domain and said second antigen binding domain of said antigen binding protein are indirectly linked.
  • said second antigen binding domain of said antigen binding protein is directly or indirectly linked to the light chain of said first antigen binding domain.
  • the C-terminus of the VHH of the second antigen-binding domain of the antigen-binding protein is directly or indirectly linked to the N-terminus of the light chain of the first antigen-binding domain.
  • the N-terminus of the VHH of the second antigen-binding domain of the antigen-binding protein is directly or indirectly linked to the C-terminus of the light chain of the first antigen-binding domain.
  • said second antigen binding domain of said antigen binding protein is directly or indirectly linked to the heavy chain of said first antigen binding domain.
  • the C-terminus of the VHH of the second antigen-binding domain of the antigen-binding protein is directly or indirectly linked to the N-terminus of the heavy chain of the first antigen-binding domain.
  • the N-terminus of the VHH of the second antigen-binding domain of the antigen-binding protein is directly or indirectly linked to the C-terminus of the heavy chain of the first antigen-binding domain.
  • said second antigen binding domain of said antigen binding protein is directly or indirectly linked to the heavy chain of said first antigen binding domain.
  • the first antigen-binding domain and the second antigen-binding domain of the antigen-binding protein are Link through linker.
  • said second antigen binding domain of said antigen binding protein is directly or indirectly linked to the light chain of said first antigen binding domain.
  • said linker of said antigen binding protein is a peptide linker.
  • said linker of said antigen binding protein comprises the amino acid sequence of (GGGGS)n, wherein n is any integer from 0-10.
  • the present application also provides a polypeptide comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises a TIGIT-targeted VHH, a linker and a light chain of an antibody targeting PD-L1, and the second polypeptide chain comprises a heavy chain of an antibody targeting PD-L1.
  • the C-terminus of the TIGIT-targeting VHH of the polypeptide is connected to the N-terminus of the PD-L1-targeting antibody light chain through a linker.
  • the N-terminus of the TIGIT-targeting VHH of the polypeptide is connected to the C-terminus of the PD-L1-targeting antibody light chain through a linker.
  • the present application also provides a polypeptide comprising a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises a PD-L1-targeting antibody light chain, and the second polypeptide chain comprises a TIGIT-targeting VHH, a linker, and a PD-L1-targeting antibody heavy chain.
  • the C-terminus of the TIGIT-targeting VHH of the polypeptide is connected to the N-terminus of the PD-L1-targeting antibody heavy chain through a linker.
  • the N-terminus of the TIGIT-targeting VHH of the polypeptide is connected to the C-terminus of the PD-L1-targeting antibody heavy chain through a linker.
  • the polypeptide comprises two first polypeptide chains and two second polypeptide chains.
  • the antibody heavy chain targeting PD-L1 of the polypeptide comprises HCDR1, HCDR2 and HCDR3, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:15, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:16, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:17.
  • the heavy chain of the antibody targeting PD-L1 of the polypeptide comprises VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:21.
  • the antibody light chain targeting PD-L1 of the polypeptide comprises LCDR1, LCDR2 and LCDR3, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:24, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:25, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:26.
  • the light chain of the antibody targeting PD-L1 of the polypeptide comprises a VL, and the VL comprises the amino acid sequence shown in SEQ ID NO:31.
  • the linker of the polypeptide comprises the amino acid sequence of (GGGGS)n, wherein n is any integer from 0-10.
  • the heavy chain of the antibody targeting PD-L1 of the polypeptide comprises the amino acid sequence shown in SEQ ID NO:23.
  • the light chain of the antibody targeting PD-L1 of the polypeptide comprises the amino acid sequence shown in SEQ ID NO:33.
  • said first polypeptide chain of said polypeptide comprises the amino acid sequence shown in SEQ ID NO:33.
  • said second polypeptide chain of said polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, and SEQ ID NO:37.
  • the present application also provides one or more isolated nucleic acid molecules encoding the antigen-binding protein or the polypeptide.
  • the present application also provides a vector comprising the nucleic acid molecule.
  • the present application also provides a cell comprising the antigen-binding protein, the polypeptide, the nucleic acid molecule, or the carrier.
  • the present application also provides a method for preparing the antigen-binding protein, the method comprising culturing the cell under the condition that the antigen-binding protein is expressed.
  • the present application also provides a pharmaceutical composition, which comprises the antigen-binding protein or the polypeptide, and optionally a pharmaceutically acceptable carrier.
  • the present application also provides the use of the antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the cell, and/or the pharmaceutical composition in the preparation of a medicament for preventing, treating and/or alleviating diseases and/or conditions.
  • the diseases and/or disorders include diseases and/or disorders associated with aberrant expression of TIGIT.
  • the disease and/or condition comprises a tumor.
  • the tumor comprises a solid tumor.
  • the tumor comprises a non-solid tumor.
  • the tumor comprises colon cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, and/or hepatocellular carcinoma.
  • the present application also provides a method for preventing, treating and/or alleviating diseases and/or conditions, said method comprising administering said antigen-binding protein, said polypeptide, said nucleic acid molecule, said carrier, said cell, and/or said pharmaceutical composition to a subject in need.
  • the diseases and/or disorders include diseases and/or disorders associated with aberrant expression of TIGIT.
  • the disease and/or condition comprises a tumor.
  • the tumor comprises a solid tumor.
  • the tumor comprises a non-solid tumor.
  • the tumor comprises colon cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, and/or hepatocellular carcinoma.
  • the present application also provides a method for blocking the interaction between TIGIT protein and CD155, the method comprising administering the antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the cell, and/or the pharmaceutical composition to a subject in need.
  • the method is an in vitro method.
  • the method is an ex vivo method.
  • the methods are non-diagnostic and therapeutic.
  • Figure 1 shows a schematic diagram of the structure of the antigen-binding protein described in this application.
  • 2A-2P show the HPLC-SEC purity test of the antigen-binding protein described in this application.
  • Figure 3A shows the detection of the binding activity of the antigen-binding protein described in the present application to human PD-L1;
  • Figure 3B shows the detection of the binding activity of the antigen-binding protein described in the present application to human TIGIT.
  • Figure 4 shows the flow cytometric detection of the binding activity of the antigen-binding protein described in this application to cynomolgus monkey TIGIT.
  • Figure 5 shows the flow cytometric detection of the blocking activity of the antigen binding proteins described in this application.
  • Figures 6A-6J show Fortebio's detection of the affinity of the antigen-binding proteins described in this application.
  • Figure 7A shows the ADCC activity of the antigen-binding protein described in the present application on PD-L1;
  • Figure 7B shows the ADCC activity of the antigen-binding protein described in the present application on TIGIT.
  • FIGS 8A-8B show the thermostability assay of the antigen binding proteins described in this application.
  • Figure 9 shows the results of tumor volume inhibition in mice in the in vivo efficacy test of the antigen-binding protein described in this application.
  • TIGIT protein or “TIGIT antigen” are used interchangeably and include any functionally active fragments, variants and homologues of TIGIT that are naturally expressed by cells or expressed on cells transfected with the TIGIT gene.
  • TIGIT may be human TIGIT, whose accession number in UniProt/Swiss-Prot is Q495A1.
  • TIGIT can be a functionally active fragment of human TIGIT.
  • such "functionally active fragments” may include fragments that retain at least one endogenous function of a naturally occurring protein (eg, binding to an antigen binding protein described herein).
  • the "functionally active fragment” may include a domain that binds to the antigen-binding protein of the present application.
  • TIGIT can be expressed on the surface of immune cells.
  • it can be expressed on the surface of regulatory T cells (Treg).
  • the term "programmed death ligand-1 (PD-L1)” is one of two cell surface glycoprotein ligands of PD-1 (the other being PD-L2), which downregulates T cell activation and cytokine secretion upon binding to PD-1.
  • the term “PD-L1” includes human PD-L1 (hPD-L1), variants, isoforms and species homologs of hPD-L1, and analogs that share at least one common epitope with hPD-L1.
  • the complete hPD-L1 sequence can be found under GenBank accession number Q9NZQ7.
  • isolated generally means obtained from the natural state by artificial means. If an "isolated" substance or component occurs in nature, it may be that its natural environment has been altered, the substance has been isolated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the high-purity identical polynucleotide or polypeptide isolated from this natural state is called isolated.
  • isolated does not exclude the admixture of artificial or synthetic substances, nor the presence of other impure substances which do not affect the activity of the substance.
  • isolated antigen-binding protein generally refers to a protein with antigen-binding ability obtained from a natural state through artificial means.
  • isolated antigen binding protein may comprise an antigen-binding moiety and, optionally, a framework or framework portion that permits the antigen-binding moiety to adopt a conformation that facilitates binding of said antigen-binding moiety to antigen.
  • Antigen binding proteins may comprise, for example, antibody-derived protein framework regions (FR) or alternative protein framework regions or artificial framework regions with grafted CDRs or CDR derivatives.
  • Such frameworks include, but are not limited to, antibody-derived framework regions comprising mutations introduced, eg, to stabilize the three-dimensional structure of the antigen binding protein, and fully synthetic framework regions comprising, eg, biocompatible polymers. see example Such as Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, 53(1): 121-129 (2003); Roque et al., Biotechnol. Prog. 20: 639-654 (2004).
  • antigen binding proteins include, but are not limited to: human antibodies , humanized antibodies; chimeric antibodies; recombinant antibodies; single chain antibodies; diabodies ; and its fragments.
  • the isolated antigen binding protein may comprise more than one antigen binding domain.
  • the antigen binding domains may target different antigens.
  • the antigen binding domains may target different epitopes of the same antigen.
  • the isolated antigen binding protein can comprise a first antigen binding domain and a second antigen binding domain.
  • the first antigen-binding domain can target PD-L1 protein
  • the second antigen-binding domain can target TIGIT protein.
  • variable domain and “variable region” are used interchangeably and generally refer to a portion of an antibody heavy and/or light chain.
  • the variable domains of the heavy and light chains may be referred to as “ VH “ and “ VL “, respectively (or “VH” and “VL”, respectively). These domains are usually the most variable parts of an antibody (relative to other antibodies of the same class) and comprise the antigen binding site.
  • variable generally means that some segments of the variable domain may have large differences in sequence between antibodies.
  • the variable domains mediate antigen binding and determine the specificity of a particular antibody for its particular antigen.
  • variability is not evenly distributed throughout the variable domains. It is usually concentrated in three segments called hypervariable regions (CDRs or HVRs) in the light and heavy chain variable domains.
  • CDRs or HVRs hypervariable regions
  • the more highly conserved portions of variable domains are called the framework regions (FR).
  • the variable domains of native heavy and light chains each comprise four FR regions, most adopting a ⁇ -sheet configuration, connected by three CDRs, which form a circular link and, in some cases, form part of the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions, and the CDRs from the other chain together contribute to the formation of the antibody's antigen-binding site (see Kabat et al, Sequences of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)).
  • antibody generally refers to an immunoglobulin or fragment or derivative thereof, encompassing any polypeptide that includes an antigen combining site, whether produced in vitro or in vivo.
  • the term includes, but is not limited to, polyclonal, monoclonal, monospecific, multispecific, nonspecific, humanized, single chain, chimeric, synthetic, recombinant, hybrid, mutated and grafted antibodies.
  • the term “antibody” also includes antibody fragments, such as Fab, F(ab') 2 , Fv, scFv, Fd, dAb and other antibody fragments that retain antigen binding function (e.g., specifically bind TIGIT). Typically, such fragments will include the antigen binding domain.
  • the basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains.
  • IgM antibodies are composed of 5 basic heterotetrameric units and another polypeptide called the J chain, and contain There are 10 antigen-binding sites, whereas IgA antibodies consist of 2-5 basic 4-chain units that can be combined and polymerized with the J chain to form multivalent assemblies.
  • the 4-chain unit is typically about 150,000 Daltons.
  • Each L chain is linked to an H chain by a covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype.
  • Each H and L chain also has regularly spaced intrachain disulfide bridges.
  • Each H chain has a variable domain (VH) at the N-terminus followed by three constant domains (CH) for the alpha and gamma chains each, and four CH domains for the mu and epsilon isoforms.
  • Each L chain has a variable domain (VL) at its N-terminus and a constant domain at its other end. VL corresponds to VH, and CL corresponds to the first constant domain (CH1) of the heavy chain. Certain amino acid residues are believed to form the interface between the light and heavy chain variable domains. VH and VL pair together to form a single antigen-binding site.
  • immunoglobulins can be assigned to different classes, or isotypes. There are currently five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, with heavy chains designated alpha, delta, epsilon, gamma, and mu, respectively.
  • the gamma and alpha classes are further divided into subclasses based on relatively minor differences in CH sequence and function, eg, humans express the following subclasses: IgGl, IgG2A, IgG2B, IgG3, IgG4, IgAl and IgKl.
  • CDR also referred to as “complementarity determining region” generally refers to the region in the variable domain of an antibody, the sequence of which is highly variable and/or forms a structure-defining loop.
  • antibodies comprise six CDRs; three in the VH (HCDR1, HCDR2, HCDR3), and three in the VL (LCDR1, LCDR2, LCDR3).
  • naturally occurring camelid antibodies consisting only of heavy chains are capable of functioning and stabilizing in the absence of light chains. See, eg, Hamers-Casterman et al., Nature 363:446-448 (1993); Sheriff et al, Nature Struct. Biol. 3:733-736 (1996).
  • variable domains of native heavy and light chains each comprise four FR regions, four in VH (H-FR1, H-FR2, H-FR3, and H-FR4), and four in VL (L-FR1, L-FR2, L-FR3, and L-FR4).
  • VL of an isolated antigen binding protein described herein can include the framework regions L-FR1, L-FR2, L-FR3, and L-FR4.
  • the VH of the isolated antigen binding proteins described herein can include framework regions H-FR1, H-FR2, H-FR3, and H-FR4.
  • the term "antigen-binding fragment” generally refers to one or more fragments that have the ability to specifically bind an antigen (eg, TIGIT).
  • the antigen-binding fragment may include Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv and/or dAb.
  • Fab generally refers to an antigen-binding fragment of an antibody.
  • papain can be used Digest intact antibodies. Papain digestion of antibodies yields two identical antigen-binding fragments, the "Fab” fragment, and a residual "Fc” fragment (ie, the Fc region, supra).
  • Fab fragments may consist of a complete L chain with the variable region of a heavy chain and the first constant region ( CH 1 ) of the H chain ( VH ).
  • Fab' fragment generally refers to a monovalent antigen-binding fragment of a human monoclonal antibody, which fragment is slightly larger than a Fab fragment.
  • a Fab' fragment may include all of the light chain, all of the variable domains of the heavy chain, and all or part of the first and second constant domains of the heavy chain.
  • a Fab' fragment may also include part or all of the 220-330 amino acid residues of the heavy chain.
  • F(ab')2 generally refers to antibody fragments produced by pepsin digestion of intact antibodies.
  • the F(ab')2 fragment contains two Fab fragments and part of the hinge region held together by disulfide bonds.
  • F(ab')2 fragments have bivalent antigen binding activity and are capable of cross-linking antigen.
  • Fv fragment generally refers to a monovalent antigen-binding fragment of a human monoclonal antibody comprising all or part of the heavy and light chain variable regions and lacking the heavy and light chain constant regions.
  • the heavy and light chain variable regions include, for example, CDRs.
  • an Fv fragment includes all or part of the approximately 110 amino acid amino-terminal variable regions of the heavy and light chains.
  • the term "scFv” generally refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguous (e.g. via a synthetic linker such as a short flexible polypeptide linker) and capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it was derived.
  • a scFv may have the VL and VH variable regions described in any order (e.g., relative to the N-terminal and C-terminal of the polypeptide), and the scFv may include a VL-linker-VH or may include a VH-linker-VL.
  • the term “dAb” generally refers to an antigen-binding fragment having a VH domain, a VL domain or having a VH domain or a VL domain, see for example Ward et al. WO 06/003388 and other published patent applications of Domantis Ltd.
  • monoclonal antibody generally refers to a preparation of antibody molecules of single molecular composition.
  • Monoclonal antibodies are usually highly specific against a single antigenic site. Furthermore, each monoclonal antibody is directed against a single determinant on the antigen, unlike conventional polyclonal antibody preparations, which typically have different antibodies directed against different determinants.
  • monoclonal antibodies have the advantage that they can be synthesized by hybridoma cultures without contamination from other immunoglobulins.
  • the modifier "monoclonal” denote the characteristics of an antibody obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring that the antibody be produced by any particular method.
  • monoclonal antibodies used herein can be produced in hybridoma cells, or can be produced by recombinant DNA methods.
  • chimeric antibody generally refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species.
  • the variable regions are derived from an antibody of a laboratory animal, such as a rodent ("parent antibody”), and the constant regions are derived from a human antibody, such that the resulting chimeric antibody is less likely to elicit an adverse immune response in a human individual than the parental (e.g., mouse-derived) antibody.
  • humanized antibody generally refers to an antibody in which some or all of the amino acids other than the CDR region of a non-human antibody (such as a mouse antibody) are replaced with corresponding amino acids derived from human immunoglobulins. In the CDR regions, small additions, deletions, insertions, substitutions or modifications of amino acids may also be permissible so long as they still retain the ability of the antibody to bind a particular antigen.
  • a humanized antibody optionally will comprise at least a portion of a human immunoglobulin constant region.
  • a "humanized antibody” retains antigen specificity similar to the original antibody.
  • “Humanized” forms of non-human (eg, murine) antibodies may contain, at a minimum, chimeric antibodies of sequence derived from non-human immunoglobulin.
  • CDR region residues in a human immunoglobulin may be replaced with CDR region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired properties, affinity and/or capabilities.
  • donor antibody such as mouse, rat, rabbit or non-human primate having the desired properties, affinity and/or capabilities.
  • FR region residues of the human immunoglobulin may be replaced with corresponding non-human residues.
  • humanized antibodies can comprise amino acid modifications that are absent in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody properties, such as binding affinity.
  • Fully human antibody generally refers to an antibody that comprises only human immunoglobulin protein sequences. Fully human antibodies may contain murine sugar chains if they are produced in mice, in mouse cells, or in hybridomas derived from mouse cells. Similarly, a “mouse antibody” or “rat antibody” refers to an antibody comprising only mouse or rat immunoglobulin sequences, respectively. Fully human antibodies can be produced in humans, in transgenic animals with human immunoglobulin germline sequences, by phage display or other molecular biology methods. Exemplary techniques that can be used to make antibodies are described in US Patents: 6,150,584, 6,458,592, 6,420,140. Other techniques, such as using libraries, are known in the art.
  • the term “directly connected” is opposite to the term “indirectly connected”, and the term “directly connected” generally refers to a direct connection.
  • the direct connection may be a case where substances are directly connected without a spacer.
  • the spacer may be a linker.
  • the linker can be a peptide linker.
  • the term “indirectly linked” generally refers to the situation where substances are not directly linked.
  • the indirect connection may be through a spacer.
  • the C-terminus of L-FR1 may be directly or indirectly linked to the N-terminus of LCDR1.
  • isolated nucleic acid molecule generally refers to an isolated form of nucleotides of any length, deoxyribonucleotides or ribonucleotides, or analogs isolated from their natural environment or artificially synthesized.
  • vector generally refers to a nucleic acid delivery vehicle into which a polynucleotide encoding a protein can be inserted and the protein can be expressed.
  • the vector can be expressed by transforming, transducing or transfecting the host cell, so that the genetic material elements carried by it can be expressed in the host cell.
  • vectors may include: plasmids; phagemids; cosmids; artificial Chromosomes such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as lambda phage or M13 phage and animal viruses.
  • Animal virus species used as vectors may include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40).
  • retroviruses including lentiviruses
  • adenoviruses such as herpes simplex virus
  • poxviruses such as herpes simplex virus
  • baculoviruses such as baculoviruses
  • papillomaviruses such as SV40
  • a vector may contain a variety of elements that control expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes.
  • the vector may also contain an origin of replication.
  • Vectors may also include components that facilitate their entry into cells, such as viral particles, liposomes or protein coats, but not only
  • the term "cell” generally refers to a single cell, cell line, or cell culture that can be or has been the recipient of a subject's plasmid or vector, which includes a nucleic acid molecule of the invention or a vector of the invention.
  • Cells can include progeny of a single cell. Due to natural, accidental or deliberate mutations, the progeny may not necessarily be completely identical (either in the morphology of the total DNA complement or in the genome) to the original parent cell.
  • Cells may include cells transfected in vitro with the vectors described herein.
  • the cells can be bacterial cells (e.g., E.
  • the cells are mammalian cells. In certain embodiments, the mammalian cells are HEK293 cells.
  • the term "pharmaceutical composition” generally refers to a composition for preventing/treating a disease or condition.
  • the pharmaceutical composition may comprise the isolated antigen binding protein described herein, the nucleic acid molecule described herein, the carrier described herein and/or the cell described herein, and optionally a pharmaceutically acceptable adjuvant.
  • the pharmaceutical composition may also comprise suitable formulations of one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and/or preservatives.
  • the acceptable ingredients of the compositions are preferably nontoxic to recipients at the dosages and concentrations employed.
  • Pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions.
  • pharmaceutically acceptable carrier generally includes pharmaceutically acceptable carriers, excipients or stabilizers that are nontoxic to cells or mammals to which they are exposed at the dosages and concentrations employed.
  • Physiologically acceptable carriers can include, for example, buffers, antioxidants, low molecular weight (less than about 10 residues) polypeptides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides, and other carbohydrates, chelating agents, sugar alcohols, salt-forming counterions, such as sodium; and/or nonionic surfactants.
  • the term “specific binding” or “specific” generally refers to a measurable and reproducible interaction, such as the binding between a target and an antibody, that can determine the presence of a target in the presence of a heterogeneous population of molecules, including biomolecules.
  • an antibody that specifically binds a target (which may be an epitope) can be an antibody that binds that target with greater affinity, avidity, greater ease, and/or for a greater duration than it binds other targets.
  • the antibody specific Epitopes on sex-binding proteins that are conserved among proteins of different species.
  • specific binding can include, but does not require exclusive binding.
  • subject generally refers to human or non-human animals, including but not limited to cats, dogs, horses, pigs, cows, sheep, rabbits, mice, rats or monkeys.
  • tumor generally refers to a neoplasm or solid lesion formed by abnormal cell growth.
  • a tumor may be a solid tumor or a non-solid tumor.
  • a tumor may be a disease and/or disorder associated with abnormal expression of TIGIT.
  • cancer generally refers to a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread to other parts of the body locally or through the bloodstream and lymphatic system. Cancer in this application includes but not limited to gastric cancer, colon cancer and the like.
  • tumor and cancer are used interchangeably herein, eg, both terms encompass solid tumors and liquid tumors, eg, diffuse or circulating tumors.
  • cancer or “tumor” can include premalignant as well as malignant cancers and tumors.
  • protein, polypeptide and/or amino acid sequence involved should also be understood to include at least the following scope: variants or homologues having the same or similar functions as the protein or polypeptide.
  • the variant may be, for example, a protein or polypeptide that undergoes substitution, deletion or addition of one or more amino acids in the amino acid sequence of the protein and/or the polypeptide (for example, an antibody or fragment thereof that specifically binds to PD-L1 and/or TIGIT protein).
  • the functional variant may comprise a protein or polypeptide having amino acid changes through at least 1, such as 1-30, 1-20 or 1-10, and such as 1, 2, 3, 4 or 5 amino acid substitutions, deletions and/or insertions.
  • Said functional variant may substantially retain the biological properties of said protein or said polypeptide prior to alteration (eg, substitution, deletion or addition).
  • the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (eg, antigen binding ability) of the protein or polypeptide prior to the alteration.
  • the substitutions may be conservative substitutions.
  • the homologue may be a protein or polypeptide having at least about 85% (for example, at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or higher) sequence homology with the amino acid sequence of the protein and/or the polypeptide (for example, an antibody or fragment thereof that specifically binds to PD-L1 and/or TIGIT protein).
  • the homology generally refers to the similarity, similarity or association between two or more sequences.
  • the "percentage of sequence homology" can be calculated by comparing the two sequences to be aligned within a comparison window and determining the presence of the same nucleic acid base (for example, A, T, C, G, I) or the same amino acid residue (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) in the two sequences To obtain the number of matching positions, the number of matching positions was divided by the total number of positions in the comparison window (ie, window size), and the result was multiplied by 100 to yield the percent sequence identity.
  • the same nucleic acid base for example, A, T, C, G, I
  • the same amino acid residue for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe,
  • Alignment for purposes of determining percent sequence homology can be accomplished in various ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared or over a region of sequence of interest.
  • the homology can also be determined by the following methods: FASTA and BLAST.
  • a description of the FASTA algorithm can be found in WRPearson and DJ Lipman, "Improved Tools for Biological Sequence Comparison", Proc.
  • a description of the BLAST algorithm can be found in S. Altschul, W. Gish, W. Miller, EW Myers and D. Lipman, "A Basic Local Alignment Search Tool", J. Molecular Biology, 215:403-410,1990.
  • the term "about” generally refers to a variation in the range of 0.5%-10% above or below the specified value, such as within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified value. .
  • the CDR of an antibody also known as the complementarity determining region, is part of the variable region.
  • the amino acid residues in this region may make contacts with the antigen or antigenic epitope.
  • Antibody CDRs can be determined by various coding systems, such as CCG, Kabat, Chothia, IMGT, Kabat/Chothia, etc. These coding systems are known in the art, see http://www.bioinf.org.uk/abs/index.html#kabatnum for details. Those skilled in the art can use different coding systems to determine the CDR region according to the sequence and structure of the antibody. There may be differences in the CDR regions using different coding systems.
  • the CDR covers the CDR sequence divided according to any CDR division method; it also covers its variants, and the variant includes the amino acid sequence of the CDR being substituted, deleted and/or added with one or more amino acids.
  • the variant includes the amino acid sequence of the CDR being substituted, deleted and/or added with one or more amino acids.
  • the CDR may be divided according to the Kabat method.
  • the isolated antigen-binding protein may comprise a first antigen-binding domain capable of specifically binding to PD-L1 or a functionally active fragment thereof.
  • the first antigen-binding domain may comprise an antibody or an antigen-binding fragment thereof or a variant thereof.
  • the antibody may be selected from the following groups: monoclonal antibody, single chain antibody, chimeric antibody, humanized antibody and fully human antibody.
  • the antigen-binding fragment can be selected from the following group: Fab, Fab', Fv fragment, F(ab)' 2 , scFv, di-scFv and/or dAb.
  • the first antigen-binding domain may comprise at least one CDR in the heavy chain variable region VH, and the VH may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen-binding domain of the antigen-binding protein may comprise HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:17.
  • the first antigen-binding domain of the antigen-binding protein may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:16.
  • the first antigen-binding domain of the antigen-binding protein may comprise HCDR1, and the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:15.
  • the first antigen-binding domain of the antigen-binding protein may comprise HCDR1, HCDR2 and HCDR3, the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:15, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:16, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:17.
  • the first antigen-binding domain of the antigen-binding protein may comprise VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen-binding domain of the antigen-binding protein may comprise H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 may comprise the amino acid sequence shown in SEQ ID NO: 18.
  • the first antigen-binding domain of the antigen-binding protein may comprise H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 may comprise the amino acid sequence shown in SEQ ID NO:19.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 may comprise the amino acid sequence shown in SEQ ID NO:20.
  • the first antigen-binding domain of the antigen-binding protein comprises H-FR4, and the N of the H-FR4 The end is connected to the C-terminus of the HCDR3, and the H-FR4 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the first antigen-binding domain of the antigen binding protein may contain H-FR1, H-FR2, H-FR3, and H-FR4.
  • the H-FR1 may contain the amino acid sequence shown in SEQ ID NO: 18.
  • the H-FR3 may contain the amino acid sequence shown in the SEQ ID NO: 20, and the H-FR4 can contain the amino acid sequence shown in the SEQ ID NO: 10.
  • the first antigen-binding domain of the antigen-binding protein may comprise VH, and the VH may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the first antigen-binding domain of the antigen-binding protein may comprise LCDR3, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the first antigen-binding domain of the antigen-binding protein may comprise LCDR2, and the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:25.
  • the first antigen-binding domain of the antigen-binding protein may comprise LCDR1, and the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:24.
  • the first antigen-binding domain of the antigen-binding protein may comprise LCDR1, LCDR2 and LCDR3, the LCDR1 may comprise the amino acid sequence shown in SEQ ID NO:24, the LCDR2 may comprise the amino acid sequence shown in SEQ ID NO:25, and the LCDR3 may comprise the amino acid sequence shown in SEQ ID NO:26.
  • the first antigen-binding domain of the antigen-binding protein may comprise L-FR1
  • the C-terminus of the L-FR1 is directly or indirectly connected to the N-terminus of the LCDR1
  • the L-FR1 may comprise the amino acid sequence shown in SEQ ID NO:27.
  • the first antigen-binding domain of the antigen-binding protein may comprise L-FR2, the L-FR2 is located between the LCDR1 and the LCDR2, and the L-FR2 may comprise the amino acid sequence shown in SEQ ID NO:28.
  • the first antigen-binding domain of the antigen-binding protein may comprise L-FR3, the L-FR3 is located between the LCDR2 and the LCDR3, and the L-FR3 may comprise the amino acid sequence shown in SEQ ID NO:29.
  • the first antigen-binding domain of the antigen-binding protein may comprise L-FR4, the N-terminus of the L-FR4 is connected to the C-terminus of the LCDR3, and the L-FR4 may comprise the amino acid sequence shown in SEQ ID NO:30.
  • the first antigen binding domain of the antigen binding protein may comprise L-FR1, L-FR2, L-FR3 and L-FR4,
  • the L-FR1 may comprise the amino acid sequence shown in SEQ ID NO:27
  • the L-FR2 may comprise the amino acid sequence shown in SEQ ID NO:28
  • the L-FR3 may comprise the amino acid sequence shown in SEQ ID NO:29
  • the L- FR4 may comprise the amino acid sequence shown in SEQ ID NO:30.
  • the first antigen-binding domain of the antigen-binding protein may comprise a VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the first antigen-binding domain of the antigen-binding protein may comprise VH and VL
  • the VH may comprise the amino acid sequence shown in SEQ ID NO:21
  • the VL may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from IgG.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from human IgG.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from human IgG1.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody heavy chain constant region, and the antibody heavy chain constant region may comprise the amino acid sequence shown in SEQ ID NO:22.
  • the first antigen-binding domain of the antigen-binding protein may comprise a heavy chain, and the heavy chain may comprise the amino acid sequence shown in SEQ ID NO:23.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody light chain constant region, which may be derived from Ig ⁇ .
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody light chain constant region, and the light chain constant region may comprise the amino acid sequence shown in SEQ ID NO:32.
  • the first antigen-binding domain of the antigen-binding protein may comprise a light chain, and the light chain may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the first antigen-binding domain of the antigen-binding protein may comprise a heavy chain and a light chain
  • the heavy chain may comprise the amino acid sequence shown in SEQ ID NO:23
  • the light chain constant region may comprise the amino acid sequence shown in SEQ ID NO:32.
  • the first antigen-binding domain of the antigen-binding protein may comprise an antibody or an antigen-binding fragment thereof.
  • the antigen-binding fragment may include Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv, VHH and/or dAb.
  • the antibody may be selected from the group consisting of monoclonal antibody, chimeric antibody, humanized antibody and fully human antibody.
  • the first antigen-binding domain of the antigen-binding protein may be a monoclonal antibody.
  • the second antigen-binding domain of the antigen-binding protein may comprise at least one CDR in the variable region VH of an antibody heavy chain, and the VH may comprise the amino acid sequence shown in SEQ ID NO:42.
  • the second antigen-binding domain of the antigen-binding protein may comprise HCDR3, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the second antigen-binding domain of the antigen-binding protein may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:41.
  • the second antigen-binding domain of the antigen-binding protein may comprise HCDR2, and the HCDR2 may comprise the amino acid sequence shown in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
  • the second antigen-binding domain of the antigen-binding protein may comprise HCDR1, and the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1.
  • the second antigen-binding domain of the antigen-binding protein may comprise HCDR1, HCDR2 and HCDR3, the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:1, the HCDR2 may comprise the amino acid sequence shown in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:6.
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:2
  • the HCDR3 comprises SEQ ID NO:6.
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:3
  • the HCDR3 comprises SEQ ID NO:6.
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:4
  • the HCDR3 comprises SEQ ID NO:6.
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:5
  • the HCDR3 comprises SEQ ID NO:6.
  • the second antigen-binding domain of the antigen-binding protein may comprise H-FR1
  • the C-terminus of the H-FR1 is directly or indirectly connected to the N-terminus of the HCDR1
  • the H-FR1 may comprise the amino acid sequence shown in SEQ ID NO:7.
  • the second antigen-binding domain of the antigen-binding protein may comprise H-FR2, the H-FR2 is located between the HCDR1 and the HCDR2, and the H-FR2 may comprise the amino acid sequence shown in SEQ ID NO:8.
  • the second antigen-binding domain of the antigen-binding protein may comprise H-FR3, the H-FR3 is located between the HCDR2 and the HCDR3, and the H-FR3 may comprise the amino acid sequence shown in SEQ ID NO:9.
  • the second antigen-binding domain of the antigen-binding protein may comprise H-FR4, the N-terminus of the H-FR4 is connected to the C-terminus of the HCDR3, and the H-FR4 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the second antigen binding domain of the antigen binding protein may comprise H-FR1, H-FR2, H-FR3 and H-FR4, the H-FR1 may comprise the amino acid sequence shown in SEQ ID NO:7, the H-FR2 may comprise the amino acid sequence shown in SEQ ID NO:8, the H-FR3 may comprise the amino acid sequence shown in SEQ ID NO:9, and the H-FR4 may comprise the amino acid sequence shown in SEQ ID NO:10.
  • the second antigen-binding domain of the antigen-binding protein may comprise VH, and the VH may comprise the amino acid sequence shown in SEQ ID NO:42.
  • the second antigen-binding domain of the antigen-binding protein may comprise VH, and the VH may comprise the amino acid sequence shown in any one of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
  • the second antigen-binding domain of the antigen-binding protein may comprise an antibody or an antigen-binding fragment thereof.
  • the antigen-binding fragment may include Fab, Fab', F(ab) 2 , Fv fragment, F(ab') 2 , scFv, di-scFv, VHH and/or dAb.
  • the antibody may be selected from the group consisting of monoclonal antibody, chimeric antibody, humanized antibody and fully human antibody.
  • the second antigen-binding domain of the antigen-binding protein may be VHH.
  • the VHH of the second antigen-binding domain may comprise the amino acid sequence shown in SEQ ID NO:42.
  • the VHH of the second antigen-binding domain may comprise the amino acid sequence shown in any one of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
  • the application provides an isolated antigen binding protein comprising a first antigen binding domain and a second antigen binding domain.
  • the first antigen binding domain can specifically bind PD-L1 protein.
  • the second antigen binding domain can specifically bind a TIGIT protein.
  • the first antigen binding domain can be a monoclonal antibody.
  • the second antigen binding domain can be a VHH.
  • the first antigen-binding domain and the second antigen-binding domain may be directly or indirectly linked.
  • the first antigen-binding domain may be connected to the second antigen-binding domain through a linker.
  • the linker can be a peptide linker.
  • the linker may comprise the amino acid sequence shown in any one of SEQ ID NO:38, SEQ ID NO:39 and SEQ ID NO:40.
  • the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the light chain of the first antigen-binding domain.
  • the C-terminal of the VHH of the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the N-terminal of the light chain of the first antigen-binding domain.
  • the N-terminal of the VHH of the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the C-terminal of the light chain of the first antigen-binding domain.
  • the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the heavy chain of the first antigen-binding domain.
  • the C-terminal of the VHH of the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the N-terminal of the heavy chain of the first antigen-binding domain.
  • the N-terminal of the VHH of the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the C-terminal of the heavy chain of the first antigen-binding domain.
  • the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the heavy chain of the first antigen-binding domain.
  • the first antigen-binding domain and the second antigen-binding domain of the antigen-binding protein may be linked by a linker.
  • the second antigen-binding domain of the antigen-binding protein may be directly or indirectly linked to the light chain of the first antigen-binding domain.
  • the linker of the antigen binding protein is a peptide linker.
  • the linker of the antigen-binding protein comprises the amino acid sequence of (GGGGS)n, wherein n is any integer from 0-10. For example, said n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the present application also provides a polypeptide, which may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises a VHH targeting TIGIT, a linker, and a light chain of an antibody targeting PD-L1, and the second polypeptide chain comprises a heavy chain of an antibody targeting PD-L1.
  • the C-terminus of the TIGIT-targeting VHH of the polypeptide can be connected to the N-terminus of the PD-L1-targeting antibody light chain through a linker.
  • the N-terminal of the TIGIT-targeting VHH of the polypeptide can be connected to the C-terminal of the PD-L1-targeting antibody light chain through a linker.
  • the present application also provides a polypeptide, which may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise a PD-L1-targeting antibody light chain, and the second polypeptide chain may comprise a TIGIT-targeting VHH, a linker, and a PD-L1-targeting antibody heavy chain.
  • the C-terminus of the TIGIT-targeting VHH of the polypeptide can be connected to the N-terminus of the PD-L1-targeting antibody heavy chain through a linker.
  • the N-terminal of the VHH targeting TIGIT of the polypeptide can be connected to the C-terminal of the heavy chain of the antibody targeting PD-L1 through a linker.
  • the polypeptide may comprise two first polypeptide chains and two second polypeptide chains.
  • the antibody heavy chain targeting PD-L1 of the polypeptide may comprise HCDR1, HCDR2 and HCDR3, the HCDR1 may comprise the amino acid sequence shown in SEQ ID NO:15, the HCDR2 may comprise the amino acid sequence shown in SEQ ID NO:16, and the HCDR3 may comprise the amino acid sequence shown in SEQ ID NO:17.
  • the heavy chain of the antibody targeting PD-L1 of the polypeptide may comprise VH, and the VH may comprise the amino acid sequence shown in SEQ ID NO:21.
  • the antibody light chain targeting PD-L1 of the polypeptide may include LCDR1, LCDR2 and LCDR3, the LCDR1 may include the amino acid sequence shown in SEQ ID NO:24, the LCDR2 may include the amino acid sequence shown in SEQ ID NO:25, and the LCDR3 may include the amino acid sequence shown in SEQ ID NO:26.
  • the antibody light chain targeting PD-L1 of the polypeptide may comprise VL, and the VL may comprise the amino acid sequence shown in SEQ ID NO:31.
  • the linker of the polypeptide comprises the amino acid sequence of (GGGGS)n, wherein n can be any integer from 0-10. For example, said n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the antibody heavy chain targeting PD-L1 of the polypeptide may comprise the amino acid sequence shown in SEQ ID NO:23.
  • the antibody light chain targeting PD-L1 of the polypeptide may comprise the amino acid sequence shown in SEQ ID NO:33.
  • the first polypeptide chain of the polypeptide may comprise the amino acid sequence shown in SEQ ID NO:33.
  • the second polypeptide chain of the polypeptide may comprise the amino acid sequence shown in any one of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36 and SEQ ID NO:37.
  • the two first polypeptide chains of the isolated antigen binding protein may comprise the same amino acid sequence.
  • the two second polypeptide chains of the isolated antigen binding protein may comprise the same amino acid sequence.
  • the application provides one or more nucleic acid molecules that encode the isolated antigen binding proteins described herein.
  • it may be produced or synthesized by (i) amplified in vitro, such as by polymerase chain reaction (PCR) amplification, (ii) recombinantly produced by cloning, (iii) purified, such as by enzymatic cleavage and fractionation by gel electrophoresis, or (iv) synthesized, such as by chemical synthesis.
  • PCR polymerase chain reaction
  • purified such as by enzymatic cleavage and fractionation by gel electrophoresis
  • synthesized such as by chemical synthesis.
  • the present application provides a vector, which may comprise the nucleic acid molecule described in the present application.
  • other genes may be included in the vector, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that permit proper expression of the coding region in an appropriate host. Such control elements are well known to those skilled in the art, and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation, and the like.
  • the vector can be expressed by transforming, transducing or transfecting the host cell so that the genetic material elements it carries can be expressed in the host cell.
  • Such vectors may include, for example, plasmids, cosmids, viruses, phages, or other vectors commonly used in, for example, genetic engineering.
  • the vector is an expression vector.
  • the vector may also include components that facilitate its entry into cells, such as, but not exclusively, viral particles, liposomes or protein coats.
  • the present application provides a cell, which may comprise the nucleic acid molecule or the vector described in the present application.
  • each or each host cell may comprise one or more of the nucleic acid molecules or vectors described herein.
  • each or each host cell may comprise a plurality (eg, 2 or more) or a plurality (eg, 2 or more) of the nucleic acid molecules or vectors described herein.
  • the vectors described herein can be introduced into the host cells, such as eukaryotic cells, such as cells from plants, fungal or yeast cells, and the like.
  • the cells can be bacterial cells (eg, E. coli), yeast cells, or other eukaryotic cells.
  • the vectors described herein can be introduced into the host cells by methods known in the art.
  • the present application also provides a pharmaceutical composition, which may comprise the isolated antigen-binding protein described in the present application, the polypeptide molecule described in the present application, the nucleic acid molecule described in the present application, the carrier described in the present application and/or the cell described in the present application, and optionally a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may also comprise suitable formulations of one or more (pharmaceutically effective) adjuvants, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and/or preservatives.
  • the acceptable ingredients of the compositions are preferably nontoxic to recipients at the dosages and concentrations employed.
  • Pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions.
  • the pharmaceutical compositions may also contain more than one active compound, generally those with complementary activities that do not adversely affect each other.
  • the type and effective amount of such drugs may depend, for example, on the formulation The amount and type of antagonist present, as well as the clinical parameters of the subjects.
  • the pharmaceutically acceptable carrier may include any and all solvents, dispersion media, coatings, isotonic agents and absorption delaying agents compatible with pharmaceutical administration, and are generally safe and non-toxic.
  • the pharmaceutical composition may comprise parenteral, transdermal, intracavity, intraarterial, intrathecal and/or intranasal administration or direct injection into tissue.
  • the pharmaceutical composition can be administered to a patient or subject by infusion or injection.
  • the administration of the pharmaceutical composition can be performed by different means, such as intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
  • the pharmaceutical composition can be administered without interruption. Such uninterrupted (or continuous) administration can be achieved by a small pump system worn by the patient to measure the influx of the therapeutic agent into the patient, as described in WO2015/036583.
  • the present application provides a method for preparing the antigen-binding protein.
  • the method may comprise culturing the host cell described herein under conditions such that the antigen binding protein is expressed. For example, by using appropriate medium, appropriate temperature and incubation time, etc., these methods are understood by those of ordinary skill in the art.
  • the present application also provides the use of the isolated antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the cell and/or the pharmaceutical composition in the preparation of a medicament for the prevention, alleviation and/or treatment of diseases and/or conditions.
  • the present application also provides a method for preventing, alleviating or treating a disease and/or disorder
  • the method may comprise administering the isolated antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the cell and/or the pharmaceutical composition described in the present application to a subject in need.
  • the administration can be carried out in different ways, such as intravenous, intratumoral, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
  • the isolated antigen-binding protein, the polypeptide, the nucleic acid molecule, the carrier, the cell and/or the pharmaceutical composition described in this application can be used to prevent, alleviate or treat diseases and/or conditions.
  • the diseases and/or disorders may include diseases and/or disorders associated with abnormal expression of TIGIT.
  • the diseases and/or conditions may include tumors.
  • the tumor may include solid tumors.
  • the tumor may include non-solid tumors.
  • the tumor may include colon cancer, melanoma, non-small cell lung cancer, renal cell carcinoma and/or hepatocellular carcinoma.
  • the application also provides a method for blocking the interaction between TIGIT protein and CD155, the method It may comprise administering said antigen binding protein, said polypeptide, said nucleic acid molecule, said carrier, said cell, and/or said pharmaceutical composition to a subject in need thereof.
  • the method may be an in vitro method.
  • the method may be an ex vivo method.
  • the method may be a method for non-diagnostic and therapeutic purposes.
  • the antibody targeting PD-L1 is IgG, while the antibody targeting TIGIT is nanobody. Since both are immune checkpoints, in order to achieve the best blocking effect, when designing bispecific antibodies, the bivalent binding activity similar to that of the parental antibody is retained. In addition, considering that the biological activity of TIGIT monoclonal antibody is largely dependent on the elimination of regulatory T cells in the tumor microenvironment, the Fc of IgG1 is used to retain its complete ADCC activity.
  • the specific design is shown in Figure 1.
  • the nucleotide sequences encoding peptide chains 1 and 2 are loaded into the eukaryotic expression vector pCMV, and then the vectors expressing peptide chains 1 and 2 are transfected into EXPI293 at a ratio of 2:3, and placed in a cell culture incubator. After culturing for 5 days, the supernatant was collected and purified with protein A (GenScript, catalog number: L00695-80). The amino acid sequence of the BiPT-m is shown in Table 1.
  • Anti-human IgG Fc-650 secondary antibody (abcam, product number: ab98593) was diluted 1:200 times with PBS containing 0.1% BSA, added 30 ⁇ l to each well, mixed with cells, and incubated at 4°C for 30 min. Wash the cells 3 times with PBS containing 0.1% BSA, 500g each time, centrifuge for 5min, and finally resuspend the cells in 30 ⁇ l PBS containing 0.1%BSA, put them on the machine, and use Graphpad to make a four-parameter fitting curve after reading the data, and calculate EC50.
  • the VHH sequence of hTIGI7.11E is shown in SEQ ID NO:12
  • the VH sequence of YN035 is shown in SEQ ID NO:21
  • the VL sequence of YN035 is shown in SEQ ID NO:31.
  • the results of the binding activity test are shown in Figure 3. When the Nanobody is attached to the N-terminus of the heavy chain, its binding activity is not affected. The activities of all bi-antibodies binding to PD-L1 remained consistent.
  • Anti-human IgG Fc-650 secondary antibody (abcam, product number: ab98593) was diluted 1:200 times with PBS containing 0.1% BSA, added 30 ⁇ l to each well, mixed with cells, and incubated at 4°C for 30 min. Wash the cells 3 times with PBS containing 0.1% BSA, 500g each time, centrifuge for 5min, and finally resuspend the cells in 30 ⁇ l PBS containing 0.1%BSA, put them on the machine, and use Graphpad to make a four-parameter fitting curve after reading the data, and calculate EC50. The results are shown in Figure 4. When the Nanobody is attached to the N-terminal of the heavy chain, the TIGIT binding activity of the Nanobody is not affected.
  • BiPT-22-25 Dilute BiPT-22-25 to 100nM and add antibody to 384-well plate.
  • Dilute human TIGIT-His antigen Beijing Baipu Saisi Biotechnology Co., Ltd., TIT-H52H5-100ug
  • PD-L1-His protein Dilute human TIGIT-His antigen (Beijing Baipu Saisi Biotechnology Co., Ltd., TIT-H52H5-100ug) and PD-L1-His protein to 100nM, 2-fold dilution, a total of 7 gradients, and add to a 384-well plate.
  • Use the AHC probe (Sartorius, catalog number: 18-5060), set the binding time to 180 sec, the dissociation time to 300 sec, the baseline to 60 sec, and the regeneration cycle three times, 5 sec each. Afterwards, software was used to fit the binding-dissociation curve to calculate the affinity of the antibody. The results are shown in Figure 6A-J. All bispecific antibodies BiPT
  • the target cells are: 293T-human TIGIT cells, which are 293T cell lines that can stably express human TIGIT and luciferase luciferase established in the laboratory; target cells are counted and centrifuged and then resuspended in "DMEM+10% FBS" medium, with a cell density of 2E5/ml, 50 ⁇ l/well, that is, 5000 target cells per well; a frozen PBMC, 8E7cells, was shipped from the company's warehouse; washed 3 times with PBS, 500g/5min, 400g/5min, 300g/5min, centrifuge at room temperature.
  • the antibodies were: hTIGIT7.11E, IgG1-FC, BiPTs, the initial working concentration of the antibody was 100nM, 8-fold gradient dilution, a total of 7 concentration gradients were formed, 50ul/well; , effector cells and antibodies were added together into a 96-well cell culture plate with a white background that is opaque, and a separate well of target cells was set as a control.
  • the cells were washed 3 times with PBS containing 0.1% BSA, 500 g each time, centrifuged for 5 min, and finally the cells were resuspended with 30 ⁇ l of PBS containing 0.1% BSA, put on the machine, and read the data.
  • the results are shown in Figure 8. All the double antibodies can still maintain high binding activity after incubation at 60°C for 1 hour, and have good thermal stability.
  • MC38 cells were inoculated subcutaneously on the right side of C57BL/6-hTIGIT humanized mice at a concentration of 1 ⁇ 10 6 cells/0.1 mL.
  • the route of administration for all groups was intraperitoneal injection, administered once every three days, and administered continuously for 6 times.
  • the experiment was terminated 11 days after the last administration.
  • the body weight and tumor volume of the mice were measured 3 times a week, and the measured values were recorded, and the tumor volume inhibition rate (TGITV%) was calculated.
  • TGITV% tumor volume inhibition rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une protéine de liaison à l'antigène isolée, comprenant un premier domaine de liaison à l'antigène et un second domaine de liaison à l'antigène. Le premier domaine de liaison à l'antigène peut se lier Spécifiquement à PD-L1 ; le second domaine de liaison à l'antigène peut se lier spécifiquement TIGIT ; le premier domaine de liaison à l'antigène contient au moins une CDR dans une région variable de chaîne lourde VH ; et la VH contient une séquence d'acides aminés telle que représentée par SEQ ID NO : 21.
PCT/CN2023/073040 2022-01-24 2023-01-19 Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation WO2023138638A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380018211.5A CN118591565A (zh) 2022-01-24 2023-01-19 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210079303 2022-01-24
CN202210079303.1 2022-01-24

Publications (1)

Publication Number Publication Date
WO2023138638A1 true WO2023138638A1 (fr) 2023-07-27

Family

ID=87347884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/073040 WO2023138638A1 (fr) 2022-01-24 2023-01-19 Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation

Country Status (2)

Country Link
CN (1) CN118591565A (fr)
WO (1) WO2023138638A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196309A1 (fr) * 2018-04-09 2019-10-17 上海原能细胞医学技术有限公司 Anticorps anti-pd-l1 et son utilisation
CN112661854A (zh) * 2020-12-03 2021-04-16 安徽安科生物工程（集团）股份有限公司 抗pd-l1与tigit双特异性抗体及其制备与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196309A1 (fr) * 2018-04-09 2019-10-17 上海原能细胞医学技术有限公司 Anticorps anti-pd-l1 et son utilisation
CN112661854A (zh) * 2020-12-03 2021-04-16 安徽安科生物工程（集团）股份有限公司 抗pd-l1与tigit双特异性抗体及其制备与应用

Also Published As

Publication number Publication date
CN118591565A (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
EP3882275B1 (fr) Anticorps bifonctionnel anti-pd-1 et anti-vegfa, composition pharmaceutique et utilisation associées
WO2022042690A1 (fr) Anticorps anti-ccr8 et application correspondante
CA3092456A1 (fr) Anticorps anti-tigit et utilisation connexe
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
US20240317888A1 (en) Antibodies that bind psma and gamma-delta t cell receptors
WO2022171080A1 (fr) Anticorps anti-cd112r et son utilisation
US20240182562A1 (en) Cldn18.2 antigen-binding protein and use thereof
US20240026024A1 (en) Cd73 antigen-binding protein and application thereof
KR20230066392A (ko) 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2022152144A1 (fr) Protéine de liaison à cd73 et son utilisation
KR20220071264A (ko) 항-pd-l1 항원 결합 단백질 및 이의 응용
KR20190095943A (ko) 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
WO2019192493A1 (fr) Anticorps monoclonal anti-lag-3 humain et son utilisation
WO2022206976A1 (fr) Protéine de liaison à l'antigène ciblant la cldn18.2, et son utilisation
WO2023138638A1 (fr) Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation
CA3189496A1 (fr) Anticorps de proteine anti-pvrig ou fragment d'anticorps et son utilisation
TW201840585A (zh) 用於白斑病的治療的抗人cxcr3抗體
WO2023134657A1 (fr) Protéine de liaison à l'antigène bispécifique anti-cldn18.2 et 4-1bb et son utilisation
WO2023236968A1 (fr) Protéine de liaison à l'antigène bispécifique cd39/cd73 et son utilisation
WO2022199527A1 (fr) Protéine de liaison à l'antigène ciblant la protéine hémolysine de streptococcus pneumoniae et son utilisation
WO2023109847A1 (fr) Protéine de liaison à l'antigène pd-l1 et son application
WO2022257868A1 (fr) Protéine de liaison à l'antigène contre l'albumine sérique humaine
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
TW202235436A (zh) Ｓｉｇｌｅｃ－１５結合蛋白的製備及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23742953

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE